Clinical equivalence of two cytokeratin markers in non-small cell lung cancer: A study of tissue polypeptide antigen and cytokeratin 19 fragments

Chest

Volumn 124, Issue 2, 2003, Pages 622-632

  Buccheri, Gianfranco ^a   Torchio, Pierfederico ^b   Ferrigno, Domenico ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Classification; Cytokeratin; Cytokeratin 19 fragments; Lung neoplasm; Neoplasm staging; Non small cell lung cancer; Prognosis; Tissue potypeptide antigen; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; ROC CURVE; SERUM; SURVIVAL TIME;

EID: 0043234142     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.2.622     Document Type: Article

References (50)

1. Pamies RJ, Crawford DR. Tumor markers: an update. Med Clin North Am 1996; 80:185-199
2. Coombes RC, Powels TJ. Tumour markers in the management of human cancer. In: Deeley TJ, ed. Topical reviews in radiotherapy and oncology. Bristol, UK: Wright PGS, 1982; 39
3. Buccheri G. Tumor markers: clinical meaning and use. In: Brambilla C, Brambilla E, eds. Lung tumors. New York, NY: Marcel Dekker, 1999; 435-452
4. Luna EJ, Hitt AL. Cytoskeleton-plasma membrane interactions. Science 1992; 258:955-963
5. Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer 2001; 34(suppl):S65-S69
6. Bjorklund B. Tissue polypeptide antigen (TPA): biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. In: Schonfeld H, ed. Laboratory testing for cancer. Basel, Switzerland: Karger, 1978; 16-31
7. Broers JL, Ramaekers FC, Rot MK, et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 1988; 48: 3221-3229
8. van Putten JW, Baas P, Codrington H, et al. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer 2001; 33:289-298
9. Ferrigno D, Buccheri G. Clinical applications of serum markers for lung cancer. Respir Med 1995; 89:587-597
10. Buccheri GF, Violante B, Sartoris AM, et al. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 1986; 57:2389-2396
11. Buccheri GF, Ferrigno D, Sartoris AM, et al. Tumor markers in bronchogenic carcinoma: superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 1987; 60:42-50
12. Buccheri G, Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer. Chest 1988; 93:565-569
13. Ferrigno D, Buecheri G, Rendine S. The prognostic value of CEA and TPA in the initial evaluation of lung cancer: results of a multivariate analysis of 312 patients. In: Motta G, ed. Lung cancer: advanced concepts and present status. Genova, Italy: International Association for the Study of Lung Cancer, 1989; 179-188
14. Buccheri G, Ferrigno D. Prognostic value of the tissue polyptide antigen in lung cancer. Chest 1992; 101:1287-1292
15. Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polyptide antigen (TPA), and other prognostic indicators in the squamous cell carcinoma of the lung. Lung Cancer 1993; 10:21-33
16. Buccheri G, Ferrigno D. The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: diagnostic yield and comparison with conventional staging methods. Chest 1995; 107:471-476
17. Buccheri G, Ferrigno D. Monitoring lung cancer with tissue polyptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease stares. Lung Cancer 1995; 13:155-168
18. Travis WD, Linder J, Mackay B. Classification, histology, cytology, and electron microscopy. In: Pass HI, Mitchell JB, Johnson DH, et al, eds. Lung cancer, principles and practice. Philadelphia, PA: Lippineott Williams & Wilkins, 2000; 453-495
19. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
20. Siegel S. Nonparametric statistics for the behavioral sciences. New York, NY: McGraw-Hill, 1956
21. McNeil BJ, Keeler E, Adelstein SJ. Primer on certain elements of decision making. N Engl J Med 1975; 293:211-215
22. Hanley JA, McNeil BJ. The meaning and use of the area under receiving operating characteristic (ROC) curve. Radiology 1982; 43:29-36
23. Metz CE, Herman BA, Roe CA. Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets. Med Decis Making 1998; 18:110-120
24. Kaplan EL, Meier F. Non-parametric estimation from incomplete observations. J Am Star Assoc 1958; 58:457-481
25. SAS Institute Inc. SAS/STAT user guide. Cary, NC: SAS Institute Inc, 2000
26. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiting prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35:1-39
27. Cox DR. Regression models and life tables. J R Star Soc 1972; 34:187-220
28. Generalized linear models. Cambridge, UK: Chapman and Hall University Press, 1988
29. Bjorklund B. Serological analysis of human cancer antigen. Proceedings of the VI International Congress of Microbiology. Rome, Italy; 1953; 344
30. Bodenmuller H, Banauch D, Ofenloch B, et al. Technical evaluation of a new automated tumor marker assay: the Enzymun-Test CYFRA 21-1. In: Klapdor R, ed. Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the 90th. Berlin, Germany: Springer Verlag, 1992; 137-138
31. Buccheri G, Ferrigno D. Serum biomarkers facilitate the recognition of early-stage cancer and may guide the selection of surgical candidates: a study of carcinoembuyonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2001; 122:891-899
32. Stieber P, Hasholzner U, Bodenmüller H, et al. CYFRA 21-1: a new marker in lung cancer. Cancer 1993; 72:707-713
33. Stieber P, Dienemann H, Hasholzner U, et al. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 1994; 9:82-88
34. Rastel D, Ramaioli A, Cornillie IF, et al. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer: report of the first European multicentre evaluation. Eur J Cancer 1994; 30A:601-606
35. Niklinski J, Furman M, Chyczewska E, et al. Diagnostic and prognostic value of the new turnout marker CIFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J 1995; 8:291-294
36. Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 1998; 82:1850-1859
37. Maeda Y, Segawa Y, Takigawa N, et al. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. Intern Med 1996; 35:764-771
38. Van der Gaast A, Kok TC, Kho GS, et al. Disease monitoring by the tumour markers CYFRA 21.1 and TPA in patients with non-small cell lung cancer. Eur J Cancer 1995; 31A:1790-1793
39. Dienemann H, Stieber P, Zimmermann A, et al, Tumormarker CYFRA 21-1 in non-small cell lung cancer (NSCLC): role for detection of recurrence [abstract]. Lung Cancer 1994; 11(suppl):46
40. Bréchot JM, Chevret S, Nataf J, et al, Diagnostic and prognostic value of CYFRA 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997; 33:385-391
41. Hirashima T, Takada M, Komiya T, et al. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 1998; 18:4713-4716
42. Pujol J, Boher J, Grenier J, et al. CYFRA 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001; 31:221-231
43. Foa P, Fornier M, Miceli R, et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 911 in resectable non-small cell lung cancer. Anticancer Res 1999; 19:3613-3618
44. Nisman B, Amir G, Lafair J, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999; 19:3549-3552
45. Ray P, Quantin X, Grenier J, et al. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev 1998; 22:293-304
46. Pujol JL, Grenier J, Parrat E, et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 1996; 154:725-733
47. Ebert W, Hoppe M, Muley T, et al. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Anticancer Res 1997; 17: 2875-2878
48. Huang MS, Jong SB, Tsai MS, et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and earcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir Med 1997; 91:135-142
49. Rowell NP. Postoperative radiotherapy in non-small cell lung cancer [letter]. Lancet 1998; 352:1384
50. Lequaglie C, Ravasi G, Buccheri G, et al. CYFRA 21-1 compared with TPA in lung cancer: results of a multicentric study [abstract]. Chest 1995; 108:198S